carcinogenicity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
=== Urea cycle === The urea cycle is a metabolic pathway that results in the formation of urea using one ammonium molecule from degraded amino acids, another ammonium group from aspartate and one bicarbonate molecule. This route commonly occurs in hepatocytes. The reactions related to the urea cycle produce NADH, and NADH can be produced in two different ways. One of these uses oxaloacetate. In the cytosol there are fumarate molecules. Fumarate can be transformed into malate by the actions of the enzyme fumarase. Malate is acted on by malate dehydrogenase to become oxaloacetate, producing a molecule of NADH. After that, oxaloacetate will be recycled to aspartate, as transaminases prefer these keto acids over the others. This recycling maintains the flow of nitrogen into the cell.
== Chemistry == The three major chemical groups of serotonergic psychedelics include the tryptamines, phenethylamines, and lysergamides, which each have different profiles of pharmacological activity. A number of other miscellaneous structural groups also exist.
In February 2013, the Australian Sports Anti-Doping Authority (ASADA) and the World Anti-Doping Agency (WADA) began an investigation into the legality of Essendon's supplements program during the 2012 AFL season and the preceding preseason. Thirty-four Essendon players—including Watson—were suspected of taking the banned peptide Thymosin beta-4. This quickly led to debate over whether or not a guilty verdict would see Watson stripped of the medal. The investigation and court action stretched over the following four years. Initially, the AFL Tribunal delivered a not guilty verdict in March 2015, but on appeal in the Court of Arbitration for Sport (CAS), the players were found guilty in January 2016, resulting in the suspensions of all thirty-four players. An appeal lodged against that decision in the Federal Supreme Court of Switzerland was dismissed in October 2016. Following the guilty verdict handed down by the CAS in January, it was announced the AFL Commission would meet in February to determine whether Watson would retain his Brownlow Medal; however, this decision was delayed until the outcome of the Federal Supreme Court appeal. The final decision regarding Jobe Watson's Brownlow medal win was decided by the AFL Commission in late November 2016, with Watson retrospectively ruled ineligible for the award, and the medal then awarded to the next highest vote-getters, Cotchin and Mitchell, under the normal rules regarding ineligible players; Watson had pre-empted the decision by announcing on 11 November 2016 that he would hand back the medal.
Sources: en.wikipedia.org
Unlike the other Warsaw Pact leaders, Ceaușescu had not been slavishly pro-Soviet but rather had pursued an "independent" foreign policy; Romanian forces did not join their Warsaw Pact allies in putting an end to the Prague Spring—an invasion Ceaușescu openly denounced—while Romanian athletes competed at the Soviet-boycotted 1984 Summer Olympics in Los Angeles (receiving a standing ovation at the opening ceremonies and proceeding to win 53 medals, trailing only the United States and West Germany in the overall count). Conversely, while Soviet Communist Party General Secretary Mikhail Gorbachev spoke of reform, Ceaușescu maintained a hard political line and cult of personality. The austerity programme started in 1981 and the widespread poverty it introduced made the Communist regime very unpopular. The austerity programmes were met with little resistance among Romanians and there were only a few strikes and labour disputes, of which the Jiu Valley miners' strike of 1977 and the Brașov Rebellion of November 1987 at the truck manufacturer Steagul Roșu were the most notable. In March 1989, several leading activists of the PCR criticised Ceaușescu's economic policies in a letter, but shortly thereafter he achieved a significant political victory: Romania paid off its external debt of about US$11,000,000,000 several months before the time that even the Romanian dictator expected. However, in the months following the austerity programme, shortages of goods remained the same as before.
=== 2017 === In April 2017, Chipotle first announced that their point of sale payment system was compromised during a three-week period from late March to mid-April but gave very little information about the incident. The following month, the company later revealed that 2,250 restaurants in 47 states were involved which could potentially affect hundreds of thousands of customers who may had their credit or debit card account information with security codes stolen. A few restaurants in Canada were also affected. Some security experts criticized the way Chipotle had downplayed the incident. During the same month, a credit union in New Hampshire filed a class action lawsuit on the behalf of banks and credit unions against Chipotle for failure to provide elementary credit card data security in the most recent data breach after a similar data breach that had occurred in 2004. In July 2017, Gainesville, Florida, police reported that an unidentified person took more than $17,000 from an ATM at a local credit union by stealing from 40 different accounts that can be traced directly to the data breach.
In 1800, France built Nautilus, a human-powered submarine designed by American Robert Fulton. They gave up on the experiment in 1804, as did the British, when they reconsidered Fulton's submarine design. In 1850, Wilhelm Bauer's Brandtaucher was built in Germany. It remains the oldest known surviving submarine in the world. In 1864, late in the American Civil War, the Confederate navy's H. L. Hunley became the first military submarine to sink an enemy vessel, the Union sloop-of-war USS Housatonic, using a gun-powder-filled keg on a spar as a torpedo charge. The Hunley also sank. The explosion's shock waves may have killed its crew instantly, preventing them from pumping the bilge or propelling the submarine. In 1866, Sub Marine Explorer was the first submarine to successfully dive, cruise underwater, and resurface under the crew's control. The design by German American Julius H. Kroehl (in German, Kröhl) incorporated elements that are still used in modern submarines. In 1866, Flach was built at the Chilean government's request by Karl Flach, a German engineer and immigrant. It was the fifth submarine built in the world and, along with a second submarine, was intended to defend the port of Valparaíso against attack by the Spanish Navy during the Chincha Islands War.
Alexander Bont is a character appearing in American comic books published by Marvel Comics. Created by writer Brian Michael Bendis and artist Alex Maleev, the character first appeared in Daredevil vol. 2 #66 (December 2004). Bont is one of the first villains encountered by the superhero Matt Murdock / Daredevil. Once the Kingpin of New York's criminal underworld prior to Wilson Fisk's ascent, Bont also employed the man responsible for murdering Jack Murdock. Following his release from prison, Bont returned to a New York City vastly changed from the one he had once ruled. The traditional gangsters of his era had been replaced by costumed criminals with superpowers and theatrical personas. Enraged by this shift and seeking revenge against Daredevil—the hero responsible for his imprisonment—Bont resorted to the dangerously unstable Mutant Growth Hormone, which resulted in his death. A gender-swapped version of Alexander Bont, known as Alexandra, is portrayed by Sigourney Weaver in the 2017 miniseries The Defenders, a crossover of Marvel's Netflix series set within the Marvel Cinematic Universe (MCU). In the series, Alexandra is depicted as the leader of the Hand and one of its five "fingers".
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.